Modern treatment of obesity and diabetes with GLP-1
DOI:
https://doi.org/10.59471/ijhsc202553Keywords:
Obesity, diabetes, GLP-1, efficacy, accessibilityAbstract
GLP-1 receptor agonists became established as an important tool in the treatment of obesity and type 2 diabetes. These drugs, initially developed to improve glycaemic control, demonstrated remarkable efficacy in reducing body weight. In Argentina, their approval offered new therapeutic possibilities, although their high cost limited access for many patients. In addition to promoting weight loss, these drugs improved the metabolic profile and reduced cardiovascular risk, although they also had adverse effects that required medical supervision. Their use required a comprehensive approach that included lifestyle changes and a complete medical evaluation.
References
Ma H, Lin YH, Dai LZ, et al. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023;13:e061807. doi:10.1136/bmjopen-2022-061807
Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251–61. doi:10.1007/s00125-022-05715-4. PMID: 35579691; PMCID: PMC9112245.
Li H, Yu G, Huang Q, Yang B, Nie J, Liu Y, et al. Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis. Biomed Pharmacother. 2024;171:116150. doi:10.1016/j.biopha.2024.116150. PMID: 38242040.
Guo X, Zhou Z, Lyu X, Xu H, Zhu H, Pan H, et al. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis. Horm Metab Res. 2022;54(7):458–71. doi:10.1055/a-1844-1176. PMID: 35512849.
Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22(1):41. doi:10.1186/s12933-023-01765-z. PMID: 36841762; PMCID: PMC9960425.
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–13. doi:10.1001/jama.2021.1831. PMID: 33625476; PMCID: PMC7905697.
Cai W, Zhang R, Yao Y, Wu Q, Zhang J. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2024;12:1277113. doi:10.3389/fpubh.2024.1277113. PMID: 38356942; PMCID: PMC10864442.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877–88. doi:10.1056/NEJMoa2302392. PMID: 37351564.
Silver HJ, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, et al. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. 2023;25(8):2340–50. doi:10.1111/dom.15113. PMID: 37188932; PMCID: PMC10544709.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Diego Silva Pacheco de Moraes, Marcelo Adrián Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
How to Cite
